Cero Therapeutics Holdings Inc (CERO)

$9.26 -0.20 (-2.11%)
Market Cap 3.58M
Revenue (ttm) 0.00
Net Income (ttm) -8.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 56,700
Avg Vol 1,434,446
Day's Range N/A - N/A
Shares Out 386,000.00
Stochastic %K 23%
Beta 0.48
Analysts Strong Sell
Price Target $30.00

Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 407-2376
Address:
201 Haskins Way, Suite 230, South San Francisco, United States
LordsofKarma7
LordsofKarma7 Jul. 7 at 1:51 PM
$CERO
0 · Reply
Caputxino
Caputxino Jul. 4 at 12:01 AM
$CERO just a matter of time
0 · Reply
Mel17
Mel17 Jul. 2 at 9:00 PM
$CERO reverse split and still can’t keep up with the double digit 🙄🙄🙄🙄
2 · Reply
ladyInRed143
ladyInRed143 Jul. 2 at 4:18 PM
$CERO $MULN
1 · Reply
BPler
BPler Jul. 2 at 10:41 AM
My undervalued companies picks for Q3 runner $FNKO $EVH $GPRO $CRVO $CERO Banking om Cervomed, Cero Therapeutics and GoPro the most for a potential squeeze; Funko and EVH will just run up slowly
1 · Reply
ChipPetey11
ChipPetey11 Jul. 1 at 11:26 PM
$CERO
0 · Reply
Washingtonstate
Washingtonstate Jun. 30 at 3:01 PM
$CERO you know that it’s going to rocket 🚀
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 27 at 9:16 PM
$CERO $CYN $SBET $SVRE $VOR (If you got the dips GDHG buy HOLD anything sub 1.50 is a steal … News due soon possible next week and we see $5-$10+ run .. Top holders and private investors are holding 500%+ higher than $1S so … you understand how this works right ?
0 · Reply
peapope
peapope Jun. 27 at 8:42 PM
$CERO dilution upcoming
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 27 at 8:26 PM
$CERO $CYN $SBET $SVRE $VOR ( I like this GDHG insiders are holding 56% TOP owners and 26% by individual holders = but these guys bought them 500% higher than current price … I won’t be surprised they run her $10+ but I say we should see 2.50+ soon )
0 · Reply
Latest News on CERO
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

Jun 23, 2025, 8:15 AM EDT - 14 days ago

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 17, 2025, 8:15 AM EDT - 20 days ago

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

Jun 11, 2025, 9:10 AM EDT - 26 days ago

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

Jun 6, 2025, 8:15 AM EDT - 4 weeks ago

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

Jun 2, 2025, 9:05 AM EDT - 5 weeks ago

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

May 30, 2025, 8:15 AM EDT - 5 weeks ago

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

May 8, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 30, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 25, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 24, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

Apr 22, 2025, 8:15 AM EDT - 2 months ago

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

Apr 10, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 9, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

Mar 31, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Mar 27, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Mar 19, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Mar 13, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

Mar 6, 2025, 8:15 AM EST - 4 months ago

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

Mar 5, 2025, 8:15 AM EST - 4 months ago

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

Feb 6, 2025, 8:15 AM EST - 5 months ago

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Feb 5, 2025, 8:00 PM EST - 5 months ago

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

Dec 6, 2024, 9:00 AM EST - 7 months ago

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Nov 15, 2024, 8:45 AM EST - 8 months ago

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Nov 11, 2024, 8:15 AM EST - 8 months ago

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update

Oct 21, 2024, 9:00 AM EDT - 9 months ago

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Oct 2, 2024, 9:15 AM EDT - 9 months ago

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

Sep 25, 2024, 2:49 PM EDT - 10 months ago

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Sep 25, 2024, 9:17 AM EDT - 10 months ago

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Jul 18, 2024, 7:55 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

ASLN

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Jun 13, 2024, 8:15 AM EDT - 1 year ago

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

May 15, 2024, 8:00 AM EDT - 1 year ago

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Mar 7, 2024, 7:00 AM EST - 1 year ago

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

Feb 14, 2024, 4:48 PM EST - 1 year ago

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Jun 5, 2023, 8:00 AM EDT - 2 years ago

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Dec 6, 2022, 9:18 PM EST - 2 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

Oct 31, 2022, 8:00 AM EDT - 2 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

LordsofKarma7
LordsofKarma7 Jul. 7 at 1:51 PM
$CERO
0 · Reply
Caputxino
Caputxino Jul. 4 at 12:01 AM
$CERO just a matter of time
0 · Reply
Mel17
Mel17 Jul. 2 at 9:00 PM
$CERO reverse split and still can’t keep up with the double digit 🙄🙄🙄🙄
2 · Reply
ladyInRed143
ladyInRed143 Jul. 2 at 4:18 PM
$CERO $MULN
1 · Reply
BPler
BPler Jul. 2 at 10:41 AM
My undervalued companies picks for Q3 runner $FNKO $EVH $GPRO $CRVO $CERO Banking om Cervomed, Cero Therapeutics and GoPro the most for a potential squeeze; Funko and EVH will just run up slowly
1 · Reply
ChipPetey11
ChipPetey11 Jul. 1 at 11:26 PM
$CERO
0 · Reply
Washingtonstate
Washingtonstate Jun. 30 at 3:01 PM
$CERO you know that it’s going to rocket 🚀
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 27 at 9:16 PM
$CERO $CYN $SBET $SVRE $VOR (If you got the dips GDHG buy HOLD anything sub 1.50 is a steal … News due soon possible next week and we see $5-$10+ run .. Top holders and private investors are holding 500%+ higher than $1S so … you understand how this works right ?
0 · Reply
peapope
peapope Jun. 27 at 8:42 PM
$CERO dilution upcoming
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 27 at 8:26 PM
$CERO $CYN $SBET $SVRE $VOR ( I like this GDHG insiders are holding 56% TOP owners and 26% by individual holders = but these guys bought them 500% higher than current price … I won’t be surprised they run her $10+ but I say we should see 2.50+ soon )
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 27 at 8:13 PM
GDHG I am so sorry this only bounced 10% from 1.10 to 1.23 and didn’t run 160% like my $SVRE idea this morning or 200%+ idea on $CYN and $CERO recently Or $SBET 2.76 to $124 or $VOR .14 cents ran 1.60 >> 1000% I’m swinging full into next week .. 100%-1000% potential for GDHG ✅
0 · Reply
Staunker
Staunker Jun. 27 at 6:10 PM
$CERO From what I've seen the biggest drawback with this cancer approach has been the adverse side effects. so far this not showing toxicities is a huge deal. that along with the orphan status this so so far undervalued its hard to state. my prediction is this gets bought up before the year is over.
2 · Reply
alamoflags
alamoflags Jun. 27 at 5:19 PM
$CERO ORPHAN DRUG PR 🤞🙏🏻🤞 SEND IT !🚀 $100
0 · Reply
AgA13
AgA13 Jun. 27 at 5:01 PM
$CERO
0 · Reply
BPler
BPler Jun. 27 at 3:19 PM
Perfect for a buyout and yet price is falling without reason $CERO
0 · Reply
Catchmeifucan82
Catchmeifucan82 Jun. 27 at 2:38 PM
$ONCO Added a starter. Expecting gain bid compliance later today. $GCTK. Beautiful move. $CERO. Needs more volume l.
0 · Reply
caseysurfs
caseysurfs Jun. 27 at 12:04 PM
$CERO Lets see a big green stiffy today!
0 · Reply
TheGreatesTrader
TheGreatesTrader Jun. 27 at 11:35 AM
$CERO might explode soon depending on others to help push it along.
0 · Reply
TheGreatesTrader
TheGreatesTrader Jun. 26 at 10:31 PM
$CERO very volatile! But you could be me rich. Don’t quote me.
0 · Reply
TheGreatesTrader
TheGreatesTrader Jun. 26 at 7:59 PM
$CERO the most retarded stock ever.
0 · Reply
ChipPetey11
ChipPetey11 Jun. 26 at 7:41 PM
$CERO is now on the Reg SHO threshold list. Fails-to-deliver stacking up will force shorts to cover. With low float and pressure building, we might see a sharp move once brokerage firms start closing out short positions. Watching closely — this could get interesting fast. 🧨📈
0 · Reply
ProfessorDman1
ProfessorDman1 Jun. 26 at 7:21 PM
$CERO $CORZ $CYN $JFBR $VOR ( JFBR AH $20+ ) 🔥✅
0 · Reply